EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 3.0

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates

Qiang Yang iD, Yunpeng Liu iD

RSC Medicinal Chemistry · 2025 · 16 (1) · 50-62

DOI: 10.1039/d4md00637b ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2025. Verfasst von Qiang Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Brilliant BioConsultation Ellicott City MD 21043 USA Brilliant.BioConsult@gmail.com. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fc-glycan-specific ADC is a significant advance in site-specific ADCs for cancer therapy. Notably, JSKN003 and IBI343 have demonstrated promising results in phase 1 clinical trials and are advancing into phase 3 studies.

Autor:innen und Institutionen

  • Brilliant BioConsultation Ellicott City MD 21043 USA Brilliant.BioConsult@gmail.com.
  • ChemBind LLC Atlanta GA 30303 USA yliu@chembind.com.

ORCID-Profile: Qiang Yang, Yunpeng Liu

Zitieren

APA

Yang, Q., & Liu, Y. (2025). Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates. RSC Medicinal Chemistry, 16(1), 50-62. https://doi.org/10.1039/d4md00637b

Vancouver

Yang Q, Liu Y. Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates. RSC Medicinal Chemistry. 2025;16(1):50-62. doi:10.1039/d4md00637b

BibTeX
@article{Yang2025,
  author = {Yang, Qiang and Liu, Yunpeng},
  title = {Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates},
  journal = {RSC Medicinal Chemistry},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {50--62},
  doi = {10.1039/d4md00637b}
}
Kostenlos starten →